Effect of cilazapril on exercise tolerance in congestive heart failure.
Cilazapril (C), an angiotensin-converting enzyme inhibitor with effective antihypertensive efficacy, was examined for its ability to alter exercise tolerance testing (ETT) and respiratory oxygen uptake in 33 patients with congestive heart failure (CHF). C was administered in capsules daily to patients with New York Heart Association Class II or Class III CHF for 12 weeks, in parallel double-blind treatment groups of 0 mg (n = 8), 0.5 mg (n = 8), 1.0 mg (n = 9), and 2.5 mg (n = 8). The blood pressure (BP) was reduced by 2.5 mg C: systolic BP (SBP) from 126 to 114 mm Hg; diastolic BP from 76 to 69 mm Hg. The maximum heart rate (MHR) during ETT was increased by 2.5 mg C from 137 to 143 bpm, as was the double product (MHR x maximum SBP x 0.01) from 237 to 251. There was an insignificant change in duration of exercise (548-610 s), anaerobic threshold (AT), and maximum oxygen uptake (14.1-15.7 ml/kg/min). The results suggest a positive effect of 2.5 mg C on energy utilization in CHF patients.
Corder
C N
CN
Clinical Pharmacology, Department, Oklahoma Medical Research Foundation, Oklahoma City 73104.
Rubler
S
S
Deere
L F
LF
Puls
A
A
Peguero-Rivera
A
A
Nagarajan
R
R
Harwood
W
W
D000368:Aged; D015308:Anaerobic Threshold / Q000187:drug effects; D017315:Cilazapril / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D005080:Exercise Test; D017079:Exercise Tolerance / Q000187:drug effects*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010101:Oxygen Consumption / Q000187:drug effects
D017315:Cilazapril